In response to noradrenaline, healthy perivascular adipose tissue (PVAT) exerts an anticontractile effect on adjacent small arterial tissue. Organ bath solution transfer experiments have demonstrated the release of PVAT-derived relaxing factors that mediate this function. The present studies were designed to investigate the mechanism responsible for the noradrenaline-induced PVAT anticontractile effect.
Introduction
Perivascular adipose tissue (PVAT) surrounds virtually all blood vessels and exerts an anticontractile effect in response to various vasoconstrictor agonists (Gao et al., 2007; Greenstein et al., 2009) . The mechanisms by which PVAT exerts this effect are the subject of intense investigations, and what is clear already from organ bath studies is that adipocytes release transferable relaxing factor(s) (Lohn et al., 2002; Greenstein et al., 2009 ). However, the precise identity of these is unclear.
Recent evidence has indicated that β 3 -adrenoceptors may be involved in the release of PVAT-derived relaxing factors (PDRFs) provoked by sympathomimetic hormones: Weston et al. (2013) demonstrated that the specific β 3 -agonist, CL-316243, induced endotheliumindependent but PVAT-dependent myocyte hyperpolarization in rat mesenteric artery via the opening of potassium BK Ca (K Ca 1.1) channels.
Vascular smooth muscle cell potassium channels are key regulators of membrane potential, with increased or decreased activity resulting in hyperpolarization or depolarization, respectively, meaning that they act as 'off switches' in excitable cells and occupy a central position in the regulation of vascular tone (Ghatta et al., 2006) . Myocyte membrane potential is hyperpolarized in the presence of PVAT, and substantial evidence points towards a role of potassium channels in the anticontractile mechanism. Pharmacological investigations have led to the identification of several potassium channel candidates including K v 7 (Fésüs et al., 2007; Schleifenbaum et al., 2010) and BK Ca (Gao et al., 2005; Lynch et al., 2013) , which appear to undergo differential activation depending on the vascular bed and species investigated. Collectively, these studies indicate the emerging importance of PVAT, which appears to exert its anticontractile effect through a variety of complex pathways that may be activated in parallel in response to different agonists.
Therefore, the present studies were designed to investigate the mechanisms responsible for the noradrenaline (NA)-induced PVAT anticontractile effect. We report that β 3 -adrenoceptor stimulation of adipocytes leads to Gα s signalling, a rise in cAMP and K v 7 channel activation. The PDRF is NO.
Methods

Group sizes
For all experiments, the group size is provided within the figure legends. For all experiments, the number of animals is reported. Assays for cAMP and NO were performed in duplicate and an average for each animal used for calculation of mean data.
Randomization
All rats used in this study were healthy adult male Sprague Dawley rats bred at Charles River, UK. Rats were randomly assigned to a numbered cage upon delivery from Charles River, and the animals were used when they reached an appropriate size (250-300 g). The pharmacological protocol to be used in each myograph bath was determined prior to mounting the vessels.
Blinding
Experimental blinding was not used for this study as there was one core experimenter responsible for dissection, experimental protocols and analysis. In order to limit experimental bias, data analysis was not performed until experimental data sets were complete. Duplicate data from a minimum of five separate animals were required for all experimental protocols described.
Normalization
Contractile responses are expressed as mean percentages of KPSS constriction ± SEM consistent with previously published data (Greenstein et al., 2009; Withers et al., 2011) . This allowed for comparison in contractile changes independent of vessel size.
Validity of animal model
Male Sprague Dawley rats are a well-established model for the investigation of PVAT function and vascular contractility (Greenstein et al., 2009; Aghamohammadzadeh et al., 2013) . The eNOS-deficient (eNOS À/À ) mouse model is well published and commercially available. This model was chosen to confirm the role of eNOS in our proposed mechanism. We have previously shown comparable response of mouse and rat mesenteric arteries to adrenergic stimulation (Withers et al., 2011) . Myography protocols detailed below have been validated within our laboratory for rat, mouse and human tissues (Greenstein et al., 2009) . Antibodies which were selective for rat antigens were chosen for immunohistochemistry and Western blot studies.
Ethical statement
Experiments involving the use of animals were performed in accord with the UK Animals (Scientific Procedures) Act 1986 under the authority of a valid project licence. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . The experiments were approved by The University of Manchester Ethical Review Process. All work was carried out in accordance with the Declaration of Helsinki.
Animals
Healthy male Sprague Dawley rats (250-300 g; Charles River, Harlow, Hertfordshire, UK) were killed by CO 2 inhalation with death confirmed by permanent cessation of the circulation by severing the diaphragm. The mesenteric bed was immediately removed and placed in ice-cold physiological salt solution (PSS in mmol·L À1 : 119 NaCl, 4.7 KCl, 1.17 MgSO 4 , 25 NaHCO 3 , 1.17 KH 2 PO 4 , 0.03 K 2 EDTA, 5.5 glucose and 1.6 CaCl 2 ).
Male eNOS-deficient (eNOS À/À ) mice were kindly provided by Dr Elizabeth Cottrell (Manchester, UK). eNOS À/À mice were bred in-house at the University of Manchester and used at 12-week-old. As a control for eNOS À/À mice, age-matched male C57BL6/j mice were purchased from Envigo, Belton, Leicestershire, UK. Mice were killed as described above. Mesenteric artery samples were obtained and studied as described below.
Wire myography
Small mesenteric arteries (internal diameter: 200-300 μm) both with and without PVAT were dissected and mounted on two 40 μm wires in a wire myograph (Danish MyoTech, Aarhus, Denmark, Denmark). The vessels were gassed (95% air/5% CO 2 ) and maintained in PSS at 37°C for 30 min before wall tension and diameter were normalized using a standardized procedure (Mulvany and Halpern, 1977) . Isometric tension was continuously recorded (Chart 5, v5.5, AD Instruments, Oxford, Oxfordshire, UK). Vessels were challenged with 60 mmol·L À1 high potassium PSS (KPSS in mmol·L À1 : 63.7 NaCl, 60 KCl, 1.17 MgSO 4 , 25 NaHCO 3 , 1.17 KH 2 PO 4 , 0.03 K 2 EDTA, 5.5 glucose and 1.6 CaCl 2 ) to establish viability, and functional endothelial integrity was assessed by relaxation to 10 μmol·L À1 carbachol following stable constriction with 10·μmol·L À1 noradrenaline.
When investigating the role of the endothelium, endothelium was removed by inserting equine hair into the lumen. Success in removing endothelium was tested using 10 μmol·L À1 carbachol as above.
Pharmacological assessment. Pharmacological protocols were used to study the mechanisms involved in mediating the PVAT anticontractile effect. In each case, segments from the same artery were prepared with and without PVAT and incubated either with PSS as a vehicle control or PSS containing the pharmacological tool for 30 min. The role of β 3 -adrenoceptor-mediated signalling was evaluated by incubation of vessels with the β 3 -adrenoceptor agonist, CL-316243, or the β 3 -adrenoceptor antagonist, SR 59230A. The contribution of NO to PVAT function was assessed by incubation with the non-specific NOS inhibitor, N Gmonomethyl-L-arginine (L-NMMA) (Aghamohammadzadeh et al., 2013) , and vinyl-L-NIO, which has been shown to be selective for neuronal NOS (nNOS) at a concentration of 100 nmol·L À1 (Babu and Griffith, 1998) . Protocols investigated the contribution of K + channels through incubation with the K v 7 channel inhibitor -XE 991 (Li et al., 2013) .
Following incubation with pharmacological tools, concentration-responses were constructed through the cumulative addition of noradrenaline or phenylephrine to the myograph bath (1 × 10 À7 -3.51 × 10 À5 mol·L À1 ). The use of these two vasoconstrictor agonists allowed the role of βadrenoceptor-mediated signalling to be investigated, as noradrenaline has equal affinity for α and β-adrenoceptors, whereas phenylephrine has higher affinity for αadrenoceptors (Minneman et al., 2015) .
Solution transfer experiments.
Bioassay experiments were used to study the release of relaxing factors from PVAT (Lohn et al., 2002; Gao et al., 2007; Greenstein et al., 2009) . PVAT with and without its adjacent artery was used as a donor, whereas arteries stripped of PVAT were used as recipients. Both the PVAT and recipient arteries were stimulated with 30 μmol·L À1 noradrenaline, and once a stable constriction had developed, solutions were removed from both baths and transferred from the bath containing the donor PVAT to the recipient artery without PVAT. The change in tension in the recipient artery was recorded. In order to investigate the contribution of external calcium to the anticontractile mechanism, donor PVAT with and without arteries was stimulated in PSS with (1.6 mmol·L À1 ) and without calcium. In experiments where PVAT was incubated in calcium-free PSS, the calcium concentration of the solution was restored prior to addition to the recipient artery.
Exogenous PVAT experiments. Concentration-responses to noradrenaline were also constructed in vessels devoid of PVAT but with PVAT suspended on a wire within the myograph bath (exogenous PVAT) to enable examination of the release of relaxing factors from PVAT in response to different vasoconstrictor agonists. In some experiments, exogenous PVAT was incubated with various pharmacological tools for 30 min before the return of PVAT to the myograph bath to enable further investigation of PVAT mechanisms. Exogenous PVAT was incubated with forskolin to examine the effects of Gαs activation, db-cAMP to assess the role of cAMP, L-NMMA and vinyl-L-NIO to explore the role of PVAT-derived NO and XE 991 to investigate K v 7 activation within PVAT.
Stimulation of PVAT
PVAT samples (~200 mg) were dissected from small mesenteric arteries and incubated in HEPES buffer (pH 7.4, in mmol·L À1 : 127 NaCl, 5.9 KCl, 1.2 MgSO 4 , 10 HEPES, 2.4 CaCl 2 and 11.8 glucose) in the absence (control) or presence of noradrenaline (10 μmol·L À1 ) or CL-316243 (10 μmol·L À1 ) for 30 min at 37°C. The solution surrounding the PVAT (supernatant) was removed, and both tissue and supernatant were snap frozen in liquid nitrogen and stored separately at À80°C until use.
Western blot analysis
In order to investigate the effects of noradrenaline stimulation on downstream signalling within PVAT, Western blot analysis was performed on unstimulated and stimulated PVAT lysate. PVAT samples were homogenized in RIPA buffer containing protease and phosphatase inhibitors using a FastPrep-24 5G instrument with lysing matrix 5 tubes. Protein concentrations were determined using a Bradford assay. Samples (40 μg of protein) were separated using SDS-PAGE on a 12% stain-free SDS-PAGE gel (Bio-Rad Laboratories, Watford, Hertfordshire, UK). Following electrophoresis, samples were transferred to a low-fluorescence PVDF membrane using a Trans-Blot Turbo system, and transfer was verified using stain-free imaging. Non-specific binding sites were blocked with 5% BSA in TBS-Tween (0.1% Tween), followed by overnight incubation with primary antibody at 4°C. Specific primary antibodies against AMPKα (0.27 μg·mL À1 ), phosphorylated-AMPKα (0.26 μg·mL À1 ), β 3 -adrenoceptor (5-μg·mL À1 ) and eNOS (1 μg·mL À1 ) were used. This was followed by three 10 min washes in TBS-Tween at room temperature and exposure to secondary antibody (donkey anti-rabbit HRP, 0.8 μg·mL À1 ) for 1 h at room temperature. Protein reactivity was detected using Clarity Western ECL substrate chemiluminescent detection reagent and captured digitally using the ChemiDoc MP imaging system. Stain-free technology was used as a normalization tool as it allowed normalization to total protein levels through quantification of signal intensity within the whole sample (Ferguson et al., 2005; Gurtler et al., 2013) . The chemiluminescent signal intensity of a given protein was normalized to the relative quantification of the corresponding intensity of the total protein, and changes in expression are expressed as the fold increase over unstimulated controls, assigning a value of 1 to the control. Data from each replicate were normalized and then averaged across the replicates, and data are plotted as mean ± SEM.
Immunohistochemistry
PVAT samples were placed in 4% paraformaldehyde for 18 h and subsequently processed to paraffin wax blocks prior to serial sectioning at 5 μm. Samples were de-waxed using xylene and rehydrated with ethanol prior to immunostaining for K v 7.4 expression (4 μg·mL À1 ). Heat-induced antigen retrieval was performed followed by blocking of endogenous peroxidase using 3% H 2 O 2 and block of non-specific binding sites using goat serum. Sections were incubated with anti-K v 7.4 antibody overnight, followed by 1 h incubation with Biotin-SP conjugated anti-rabbit secondary antibody (1.5 μg·mL À1 ) and detection using Vectastain ABC complex followed by the addition of 3,3 0 -diaminobenzidine (DAB) solution to allow visualization of antibody binding. Images were captured using a colour camera (Leica DFC450) mounted on a microscope (Leica DM5000).
cAMP assay
Following stimulation, PVAT samples were homogenized using a FastPrep-24 5G instrument with lysing matrix 5 tubes in ice-cold 0.1 mol·L À1 hydrochloric acid at a 1:5 ratio (w . v -1 ) to inactivate any PDEs within the sample. Samples were then centrifuged at 1000 g for 10 min to remove insoluble cellular debris and neutralized with 1 mol·L À1 sodium hydroxide. Samples were diluted 100-fold in calibrator diluent before intracellular cAMP levels were determined using the competitive enzyme immunoassay cAMP parameter assay kit.
NO levels within PVATsupernatant
NO within PVAT supernatant was converted to detectable nitrite by 3 h incubation with nitrate reductase (0.17 U·mL À1 ), glucose-6-phosphate dehydrogenase (4.17 U·mL À1 ), glucose-6-phosphate (500 μmol·L À1 ) and NADPH (1.67 μmol·L À1 ) as described previously (Verdon et al., 1995) . A Griess reagent kit was then used to determine total nitrite concentration.
Total adiponectin ELISA of PVATsupernatant
Total adiponectin levels in stimulated and non-stimulated PVAT supernatant samples were measured using a commercially available ELISA kit. Stimulated and unstimulated supernatant samples were diluted 1:750 in calibrator diluent before the assay was performed according to the manufacturer's instructions.
Data and statistical analysis
The data and statistical analysis comply with British Journal of Pharmacology guidelines (Curtis et al., 2018) . GraphPad Prism (v6, GraphPad Software, USA) was used for all statistical analyses, and P values < 0.05 were considered statistically significant. Contractile responses are expressed as mean percentages of KPSS constriction ± SEM, consistent with previously published data (Greenstein et al., 2009; Withers et al., 2011) , and curves fitted using non-linear regression analysis. LogEC 50 values were calculated from individual concentration-response curves fitted using non-linear regression analysis with a sigmoidal function. Data were analysed using two-way ANOVA following by Bonferroni post hoc test or by Student's unpaired or paired t-test as appropriate.
Materials
Myography. All salts for PSSs, noradrenaline, phenylephrine and carbachol were purchased from Sigma-Aldrich, Gillingham, Dorset, UK. All other pharmacological tools were purchased from R&D Systems, Abingdon, Oxfordshire, UK.
Western blot analysis. General consumables were purchased from Sigma-Aldrich. Reagents for RIPA buffer were purchased from Roche Diagnostics, Burgess Hill, West Sussex, UK. FastPrep-24 5G instrument was purchased from MP Biomedicals Inc., Santa Ana, California Antibodies used were as follows: AMPKα (Cell Signaling Technology, Hitchin, Hertfordshire, Cat #2603 RRID: AB_490795), phosphorylated-AMPKα (Thr 172 ) (Cell Signaling Technology, Cat #2535, RRID: AB_331250), β 3 -adrenoceptor (Novus Biologicals, Abingdon, Oxfordshire, NBP1-00716, RRID:AB_1502640), eNOS (Santa Cruz Biotechnology, Dallas, Texas, USA, Cat #sc-654 RRID: AB_631423) and donkey anti-rabbit HRP (Jackson ImmunoResearch Laboratories, Ely, Cambridgeshire, Cat #711-035-152, RRID:AB_10015282). All other Western blot materials were purchased from Bio-Rad Laboratories.
Immunohistochemistry. General consumables were purchased from Sigma-Aldrich. Antibodies purchased were as follows: K v 7.4 (Santa Cruz Biotechnology, Cat #sc-50 417, RRID: AB_2131729), Biotin-SP conjugated anti-rabbit secondary antibody (Jackson ImmunoResearch Laboratories, USA, Cat #711-065-152, RRID: AB_2340593), vectastain ABC complex and DAB solution (Vector Laboratories, Peterborough, Cambridgeshire, UK, ABC: Cat #PK-6100, RRID:AB_2336819 DAB: SK-4100, RRID:AB_2336382).
Assays. All general consumables were purchased from Sigma-Aldrich. The Griess reagent kit was purchased from Promega, Chilworth, Southampton, USA. The cAMP, adiponectin and adipokine assay kits were from R&D systems, Abingdon, Oxfordshire, USA.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology. org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently achieved in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017a,b,c) .
Results
PVAT produces a transferable anticontractile factor
In endothelium-intact segments of rat mesenteric small arteries, the vasoconstrictor response to noradrenaline ( Figure 1A) but not phenylephrine was reduced in the presence of PVAT ( Figure 1B) . The vasoconstrictor response to noradrenaline was reduced in vessels lacking PVAT with exogenous PVAT suspended in the bath ( Figure 1A ), suggesting that the anticontractile effect was due to secretion of a soluble factor.
Transfer of solutions from donor PVAT with and without an artery stimulated with noradrenaline to a recipient artery lacking PVAT pre-contracted with noradrenaline produced a significant reduction in tension ( Figure 1C) , confirming that the anticontractile effect was due to secretion of a soluble factor. Also, relaxation occurred following incubation of donor PVAT with and without an artery in calcium-free external PSS solution and transfer to a recipient artery, indicating that the anticontractile effect is calcium-independent ( Figure 1D) .
In endothelium-denuded arteries, the vasoconstrictor response to noradrenaline was not reduced by the presence of PVAT ( Figure 1E) , confirming that the anticontractile factor is endothelium-independent.
Adipocyte located β 3 -adrenergic activation produces a PVAT-derived anticontractile effect via Gα s signalling Western blot analysis indicated the presence of β 3 -adrenoceptors within the PVAT of rat mesenteric arteries
Figure 1
The anticontractile capacity of PVAT is produced by secretion of an endothelium-independent soluble factor. The presence of PVAT reduced the vasoconstrictor response to (A) noradrenaline (n = 18). The contractile response to noradrenaline was also reduced in vessels with exogenous PVAT (no PVAT vs. exogenous PVAT: P < 0.05, PVAT vs. exogenous PVAT: P = NS, n = 5 and 6 respectively). The presence of PVAT had no effect on the vasoconstrictor response to (B) phenylephrine (PVAT n = 10, no PVAT n = 12). Both donor PVAT and recipient arteries were stimulated with 30 μmol·L À1 noradrenaline prior to transfer. (C) Transfer of solution from donor PVAT to a recipient artery lacking PVAT produced a significant reduction in tension both in the presence (n = 6) and absence (n = 6) of an artery with the PVAT. (D) Transfer of solution from donor PVAT incubated in calcium-free PSS to a recipient artery produced a significant reduction in tension in the presence and absence of PVAT (n = 9) and in the absence of an artery with the PVAT (n = 8). The total external calcium concentration of the recipient bath was kept constant at 1.6 mmol·L À1 after transfer. (E) The anticontractile effect is absent in endothelium-denuded arteries (P = NS, n = 6) Data are expressed as mean ± SEM. *P < 0.05, twoway ANOVA or paired t-test.
( Figure 2A) ; therefore, we investigated the contribution of β 3 -adrenoceptor-mediated signalling to the anticontractile effect. The presence of CL-316243 had no effect on vasoconstrictor response to noradrenaline ( Figure 2B ) but reduced the effect of phenylephrine ( Figure 2C) , indicating a role for β 3 -adrenoceptor activation in mediating the anticontractile effect of noradrenaline on PVAT. Incubation of vessels with intact endothelium but lacking PVAT with CL-316243 had no effect on the vasoconstrictor response to either of the agonists tested ( Figure 2D) confirming that the changes observed are a consequence of β 3 -adrenoceptor activation within PVAT. Moreover, the β 3 -adrenoceptor antagonist, SR 59230A, increased the contractile response to noradrenaline in vessels with PVAT ( Figure 2E ) but had no effect on the response to phenylephrine ( Figure 2F ). Incubation of exogenous PVAT with forskolin had no effect on the vasoconstrictor response to noradrenaline ( Figure 3A) but reduced the effect of phenylephrine ( Figure 3B ). Incubation with db-cAMP had no effect on the vasoconstrictor response to noradrenaline ( Figure 3C ) but reduced the vasoconstrictor response to phenylephrine ( Figure 3D ). Intracellular cAMP levels were increased from Figure 2 β 3 -adrenoceptor activation contributes to the PVAT anticontractile effect. (A) Representative Western blot indicating expression of β 3 -adrenoceptors within rat mesenteric PVAT. Three independent samples were analysed from each rat on one membrane. Incubation of intact vessels with PVAT with 10 μmol·L À1 CL-316243 for 30 min did not alter the response to (B) noradrenaline (n = 5) but enhanced the anticontractile effect of (C) phenylephrine (n = 5). (D) Incubation of vessels with endothelium but lacking PVAT with 10 μmol·L À1 CL-316243 did not alter the contractile response to phenylephrine (n = 5). Incubation of mesenteric vessels with PVAT with the β 3 -adrenoceptor antagonist, 1 μmol·L À1 SR 59230A for 30 min potentiated constriction to (E) noradrenaline (n = 7) but had no effect on the contractile response to (F) phenylephrine (P = NS, n = 7). Data are expressed as mean ± SEM. *P < 0.05, two-way ANOVA.
250 ± 33 to 467.4 ± 54 pmol·mL À1 within PVAT following stimulation with CL-316243 indicating that β 3 -adrenoceptor stimulation involves Gα s signalling ( Figure 3E ).
K v 7 channel activation contributes to noradrenaline-mediated anticontractile capacity
Incubation with the K v 7 inhibitor, XE 991, did not alter the vasoconstrictor response to noradrenaline in vessels lacking PVAT ( Figure 4A ) but potentiated the response to noradrenaline in vessels with PVAT ( Figure 4B ). Incubation of exogenous PVAT with XE 991 prior to placement within the myograph bath reversed the anticontractile effect of PVAT ( Figure 4C ), indicating that K v 7 channel activation within PVAT contributes to the noradrenalineinduced anticontractile capacity. Immunostaining for K v 7.4 shows K v 7.4 expression within PVAT, the endothelial layer and the adventital layer of the mesenteric artery ( Figure 4D ).
Figure 3
Gαs signalling contributes to the noradrenaline-induced PVAT anticontractile effect. Incubation of exogenous PVAT with 1 μmol·L À1 forskolin for 30 min prior to placement within the myograph bath had no effect on the vasoconstrictor response to (A) noradrenaline (n = 6) but reduced the contractile response to (B) phenylephrine (n = 6). Incubation of vessels with PVAT with the cAMP analogue, 10 μmol·L À1 db-cAMP had no effect on constriction to (C) noradrenaline (n = 6) but reduced the vasoconstrictor response to (D) phenylephrine (n = 6). (E) Intracellular cAMP levels increased following stimulation with 10 μmol·L À1 CL-316243 (P < 0.05, n = 6). Data are expressed as mean ± SEM. *P < 0.05, two-way ANOVA.
NO produced by adipocytes plays a key role in the anticontractile effect
Western blot analysis demonstrated higher eNOS expression within PVAT than the mesenteric artery ( Figure 5A) . Incubation with the NOS inhibitor, L-NMMA, did not alter the vasoconstrictor response to noradrenaline in vessels with intact endothelium but lacking PVAT ( Figure 5B ), but the vasoconstrictor response was increased in the presence of PVAT ( Figure 5C ). Incubation of exogenous PVAT with L-NMMA prior to placement within the myograph bath increased the vasoconstrictor response to noradrenaline ( Figure 5D ), indicating that PVAT-derived NO may contribute to the noradrenaline-induced anticontractile capacity. Incubation with D-NMMA, an inactive enantiomer of L-NMMA, had no effect on the contractile response of vessels with PVAT ( Figure 5E ). Incubation of exogenous PVAT with nNOS inhibitor vinyl-L-NIO had no effect on the contractile response ( Figure 5F ), indicating that eNOS may be the NOS isoform responsible for NO release from PVAT. Moreover, the anticontractile effect of PVAT on the vasoconstrictor response to noradrenaline present in C57BL6/j mice was absent in eNOS À/À , mice indicating that eNOS activation contributes to the release of NO from PVAT ( Figure 6 ). β 3 -Adrenoceptor activation within PVAT does not alter adiponectin release Abundant amounts of adiponectin were found to be basally secreted from PVAT; however, this was unaltered following stimulation with either noradrenaline or CL-316243 (Figure 7 ).
Discussion
The present study investigated the mechanisms of the noradrenaline-induced PVAT anticontractile effect. The main findings were that (i) β 3 -adrenoceptor-mediated signalling contributes to the PVAT anticontractile effect; (ii) K v 7 channel activation within PVAT contributes to release of a PDRF; and (iii) PVAT-derived NO plays a key role in the noradrenaline-induced PVAT anticontractile effect. Consistent with previously published data (Briones et al., 2005; Garland et al., 2011; Flacco et al., 2013) , we demonstrated no functional role of β 3 -adrenoceptor-mediated signalling in the contractile response to noradrenaline in vessels lacking PVAT. This suggests that the effects observed in the present study were a consequence of β 3 -adrenoceptor activation within the PVAT. This is supported by our previous Figure 4 K v 7 channel inhibition prevents PVAT anticontractile effect. (A) Incubation of vessels lacking PVAT with the K v 7 inhibitor, XE 991 (10 μmol . L -1 ) for 30 min had no effect on the contractile response to noradrenaline (n = 6) but (B) potentiated the contractile response to noradrenaline in vessels with PVAT (n = 6). (C) Incubation of exogenous PVAT with XE 991 for 30 min prior to addition to the myograph bath produced an increase in the contractile response in vessels lacking PVAT compared to vessels with control exogenous PVAT (n = 5). (D) Immunostaining showed no staining when mesenteric bed samples were incubated with rabbit IgG (a) but clear staining within the PVAT, endothelial layer and adventitial layer of the mesenteric artery when incubated with anti-K v 7.4 antibody (b). Images were obtained at 20x magnification and scale bar represents 75 μm. Data are expressed as mean ± SEM. * P < 0.05, one-way ANOVA.
observations of β 3 -adrenoceptor expression within mouse mesenteric PVAT and the effects of adipocyte β 3 -adrenoceptor inhibition on vessel tension (Saxton et al., 2018) . In this study, we report a similar β 3 -adrenoceptor-mediated mechanism in rat PVAT and have for the first time identified PVAT-derived NO as a relaxing factor released upon β 3 -adrenoceptor activation. Adipocyte β 3 -adrenoceptors are likely activated by sympathetically derived NA. The role of β 3 -adrenoceptors in catecholamine induced lipolysis has been well characterized Rebuffe-Scrive, 1991; Robidoux et al., 2006) , and the origin of sympathetic fibres in epididymal and inguinal fat depots has been extensively studied using viral transneuronal tract tracers (Bamshad et al., 1998; Song et al., 2009; Nguyen et al., 2014) . Denervation of these fat depots will lead to a decrease in lipolysis (Rooks et al., 2005; Foster and Bartness, 2006) ; however, until recently, the importance of sympathetic nerves in PVAT was unknown. Previously, using immunohistochemistry, we have confirmed the presence of sympathetic nerves in mouse mesenteric PVAT (Saxton et al., 2018) . In addition, we confirmed a functional role for sympathetic nerves in PVAT, as pharmacological sympathetic denervation of PVAT abolished the anticontractile effect. Therefore, it is sympathetically derived NA which activates β 3 -adrenoceptors, triggering the release of a relaxing factor.
Dual coupling of β 3 -adrenoceptors to both Gα s and Gα i proteins has been reported in 3T3-F440A adipocytes (Soeder et al., 1999) . We highlight an important role of the β 3 -adrenoceptor/Gα s /cAMP signalling pathway in the PVAT anticontractile capacity as β 3 -adrenoceptor stimulation resulted in cAMP production and incubation with forskolin or db-cAMP was able to mimic the PVAT anticontractile effect. This is supported by previous studies showing that L-1 L-NMMA had no effect on the contractile response to noradrenaline (n = 5). (C) Incubation with 100 μmol.L-1 L-NMMA increased the vasoconstrictor response to noradrenaline in vessels with intact PVAT (n = 6). (D) Incubation of exogenous PVAT with μmol.L-1 L-NMMA for 30 min prior to suspension within the myograph bath produced an increase in the contractile response in vessels lacking PVAT compared to vessels with control exogenous PVAT (n = 5). (E) Incubation of vessels with PVAT with D-NMMA did not alter the contractile response to noradrenaline (n = 5). (F) Incubation of exogenous PVAT with 100 nmol.L-1 Vinyl-L-NIO for 30 min prior to suspension within the myograpth bath had no effect on contractile response (n = 8). Data are expressed mean ± SEM. * P < 0.05, two-way ANOVA.
β 3 -adrenoceptors within cultured adipocytes have a tendency towards Gα s protein coupling following stimulation with physiologically relevant catecholamine concentrations (Soeder et al., 1999; Robidoux et al., 2006) .
Our finding that K v 7 channel inhibition does not alter the contractile response to noradrenaline in vessels lacking PVAT was surprising given the key role of K v 7 channels in the regulation of vascular tone (Ng et al., 2011; Chadha et al., 2012) . The majority of studies investigating the effect of K v 7 channel inhibition on vascular tone has reported increased myogenicity in the presence of XE 991 rather than investigating its effect on the arterial response to vasoconstrictor agonists or have demonstrated activation/inhibition of currents using single-cell electrophysiology in the absence of spasmogens (Ng et al., 2011; Chadha et al., 2012) . Moreover, we found very little K v 7.4 expression within the arterial medial layer consistent with the absence of a functional role, and our data are supported by an earlier myograph study using rat mesenteric artery (Li et al., 2013) . Substantial evidence suggests a role for voltage-gated K + channels, especially K v 7 in mediating the PVAT anticontractile effect in resistance arteries (Verlohren et al., 2004; Schleifenbaum et al., 2010; Zavaritskaya et al., 2013) . For the first time, we have shown K v 7.4 expression within PVAT and that specific inhibition of K v 7 within PVAT reversed the noradrenaline-induced anticontractile effect in health. This suggests a crucial role for activation of K v 7 located within PVAT in mediating the release of a relaxing factor in health. These findings contradict previous studies that suggested a role for vascular smooth muscle K v 7 channels in mediating the anticontractile effect (Fang et al., 2009; Schleifenbaum et al., 2010; Zavaritskaya et al., 2013) . However, our experimental design allowed specific inhibition of K v 7 within PVAT without affecting smooth muscle channels enabling identification of the tissue location of the channels involved in the PVAT anticontractile effect. Moreover, previous studies did not investigate K v 7 expression within PVAT, and on the basis of their results, a role for PVAT K v 7 activation could not be excluded.
Our data showing a crucial role for K v 7 within the adipocytes are supported by observations of voltage-gated K + channels within rat white adipocytes (Ramirez-Ponce et al., 1996) that can be modulated by noradrenaline and cAMP (Ramirez-Ponce et al., 1998) . Moreover, evidence has emerged that K v 7 channel activation contributes to the vasodilator response induced by β-adrenoceptor agonists through a mechanism involving cAMP and PKA, because K v 7 channel inhibitor linopirdine was able to inhibit relaxations induced by isoprenaline and forskolin (Chadha et al., 2012) , and phosphorylation of K v 7.4 by PKA has been reported to shift the activation curve leading to enhanced K v 7.4 activity (Chambard and Ashmore, 2005) . Taken together with the observed increased cAMP levels, we suggest that β 3 -adrenoceptor stimulation within PVAT and subsequent cAMP production leads to K v 7 activation. This leads to the movement of potassium out of the adipocyte down its electrochemical gradient and hyperpolarization that drives calcium entry with subsequent activation of downstream signalling pathways leading to the release of NO.
Consistent with earlier work, we were able to show that PVAT releases a transferable factor (Lohn et al., 2002;  
Figure 7
Total adiponectin secretion from PVAT is not altered by β 3 -adrenoceptor activation. Total adiponectin released from PVAT into surrounding solution was not increased by adrenergic stimulation (n = 6).
Figure 6
The PVAT anticontractile effect is lost in eNOS À/À mice. (A) In C57BL6/j mice, the vasoconstrictor response to noradrenaline is reduced in the presence of PVAT (n = 8). (B) The presence of PVAT had no effect on the vasoconstrictor response to noradrenaline in mesenteric arteries from eNOS À/À mice (n = 8). Data are expressed as mean ± SEM. *P < 0.05, two-way ANOVA. Greenstein et al., 2009; Lynch et al., 2013) , and we demonstrate that this factor is adipocyte-derived NO as the anticontractile effect reversed in the presence of specific PVAT NOS inhibition and stimulation with CL-316243, but not phenylephrine increased NO release from PVAT. Consistent with previous studies, the effects of this factor are endothelium-independent (Greenstein et al., 2009; Saxton et al., 2018) . Several studies have demonstrated a link between β 3 -adrenoceptor-mediated signalling and NO production by adipocytes (Canova et al., 2006; Hodis et al., 2011) , and recent electrophysiological studies in non-contracted vessels demonstrated that β 3 -adrenoceptor-mediated stimulation of PVAT produced myocyte hyperpolarization that could be partially reversed by the presence of L-NMMA . Moreover, our data support previous findings in human s.c. arteries (Greenstein et al., 2009 ) and mouse mesenteric arteries (Lynch et al., 2013) where NOS inhibition was reported to attenuate PVAT function, and we have recently shown a crucial role for activation of PKG, a downstream signalling component in the NO pathway, in the noradrenaline-induced anticontractile effect in mice (Withers et al., 2014) .
L-NMMA inhibits all three isoforms of NOS (eNOS, nNOS and iNOS) but may also have non-specific effects. However, the lack of effects of the inactive enantiomer, D-NMMA, and the specific nNOS inhibitor, vinyl-L-NIO, strongly suggested that the observed effects of L-NMMA in rat PVAT were a consequence of eNOS inhibition. Endothelial NOS (eNOS) plays a key role in white adipose tissue metabolism (Sansbury et al., 2012) and is activated by increased intracellular calcium (Busse and Mulsch, 1990) . Moreover, the PVAT anticontractile effect was absent in eNOS À/À mice, and we were able to detect greater eNOS expression in PVAT than
Figure 8
Proposed pathway for nitric oxide release by PVAT and how it results in the PVAT anticontractile effect. Noradrenaline (NA) activates β 3adrenoceptors within PVAT leading to increased cAMP production. This activates K v 7 within PVAT leading to an efflux of potassium and subsequent hyperpolarisation that drives calcium entry into the adipocyte and activation of endothelial nitric oxide synthase (eNOS) which catalyses the production of NO from L-arginine (L-Arg). NO is released from PVAT and acts on vascular smooth muscle cells leading to hyperpolarisation and vasodilatation which opposes vasoconstriction resulting in an anticontractile effect.
Vasodilator PVAT function in small arteries mesenteric artery suggesting that it is the key NOS isoform catalyzing NO production within PVAT.
Adiponectin promotes NO production within the endothelium (Cheng et al., 2007) , and previous studies within our laboratory have suggested a key role for adiponectin as a relaxing factor mediating the anticontractile effect in human s.c. (Greenstein et al., 2009) and mouse mesenteric (Lynch et al., 2013) arteries and in response to β 3 -adrenoceptor-mediated stimulation of non-contracted rat mesenteric arteries . Also, serum levels of adiponectin were increased in rats following 7 day infusion of CL-316243 (Zhang et al., 2002) , and adiponectin secretion from mouse mesenteric PVAT is significantly reduced when incubated with SR 59230A (Saxton et al., 2018) . Previously, adiponectin has been shown to induce vasorelaxation in rat (Greenstein et al., 2009) and mouse (Lynch et al., 2013) mesenteric arteries and myocyte hyperpolarization in noncontracted vessels . We observed high basal adiponectin secretion from PVAT; however, no changes in total adiponectin secretion were observed following stimulation with noradrenaline or CL-316243. This may be because biologically relevant changes in the ratio of high MW : low MW isoforms could not be detected using commercially available ELISA kits (Brochu-Gaudreau et al., 2010) . AMPK is a major downstream target of adiponectin (Yamauchi et al., 2007) , and we show AMPK phosphorylation in unstimulated PVAT was not altered by β-adrenoceptor-mediated stimulation, suggesting that adiponectin may be constitutively released from PVAT and could facilitate NO production by the adipocytes in response to stimulation of β-adrenoceptors.
The results presented show that adipocyte β 3 -adrenoceptor stimulation leads to increased intracellular cAMP production and KCNQ activation via increased intracellular calcium leading to release of relaxing factors, one of which is NO (Figure 7) . For the first time, we demonstrate that noradrenaline stimulates release of adipocyte-derived NO. This NO is a key PDRF and modulates arterial contraction (Figure 8 ). These findings support the targeting of NOS for the treatment of PVAT dysfunction associated with obesity and the metabolic syndrome.
